In recent days, Marcelina Zawisza (Left) informed about the submission of an interpellation by a group of deputies. The deputy pointed out that although the very decision to finance Zolgensma from public funds (the so-called gene therapy) for children up to 6 months of age is great news, it is doubtful that older children who meet the body weight criterion provided by the manufacturer could also benefit from treatment. - This is what is done, for example, in the United States, where cases of administering the drug to children up to 2 years of age are described - she reminded.
But the MPs of Razem put questions to the ministry beyond the dispute over the age criterion in the drug program. They want to know, among other things:
- Due to the fact that children over...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
